20 December 2019

3SBio Inc.’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) and Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific antibodies for the therapy of cancer based on Numab’s technology platform. Under the agreement, Sunshine Guojian has the right to select up to five antibody molecules emerging from up to three multi-specific antibody programs based on Numab’s R&D platform and has the exclusive licenses to develop and commercialize each of the selected antibody molecules in Greater China territories, including the Mainland China, Hong Kong, Macao and Taiwan, while Numab retains exclusive commercial rights in the rest of the world. Concurrently, Sunshine Guojian has invested CHF15M (approximately USD 15.2M) in Numab’s series B financing. Dr. Zhenping Zhu, MD, PhD, President of Research and Development, Chief Scientific Officer of 3SBio, has joined Numab’s board of directors.

VISCHER acted as counsel to Numab. The team was led by Stefan Kohler (IP/Life Sciences) and Christian Wyss (Corporate), supported by Christoph Niederer (Tax), Lukas Zuest (VISCHER China Desk), Luzius Zumstein (Corporate) and Francesca Pesenti (Corporate).

Categories: China Desk, Corporate and Commercial, Intellectual Property, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital

You are currently offline. Some pages or content may fail to load.